July 2015 - Biowebspin | Biowebspin
Logo Biowebspin

Archives July 2015 - Biowebspin

A European biotechnology transfer platform?

A European biotechnology transfer platform?

  Biowebspin, July 30th, 2015 A European biotechnology transfer platform? by Christian Suojanen, in New Biotechnology, 2009   See the article and check access: If you can't access this article, do not hesitate to contact us. »

Biopharma CRO industry in China: landscape and opportunities

Biopharma CRO industry in China: landscape and opportunities

  Biowebspin, July 30th, 2015 Biopharma CRO industry in China: landscape and opportunities by Christine Xia, Ajay Gautam, in Drug Discovery Today, 2015 The pharmaceutical industry has responded to the declining research and development (R&D) productivity over the past decade by decreasing its cost base and outsourcing parts of drug research, with China increasingly being the preferred destinat... »

Challenges and Opportunities in process innovation

Challenges and Opportunities in process innovation

  Biowebspin, July 30th, 2015 Challenges and Opportunities in process innovation by Larry R. Genskow, in Computer Aided Chemical Engineering, 2006 This addresses key challenges and opportunities in process innovation. Important capability trends are identified and discussed. Key challenges and opportunities to be addressed include: 1)The challenge of learning at the smallest scale to increase inno... »

Current trends in the pharmaceutical industry – A case study approach

Current trends in the pharmaceutical industry – A case study approach

  Biowebspin, July 30th, 2015 Current trends in the pharmaceutical industry – A case study approach by Alexandru Rusu, Katja Kuokkanen, Annabelle Heier, in European Journal of Pharmaceutical Sciences, 2011 This commentary offers an overview of some current trends of the pharmaceutical industry drawing on examples taken from the analysis of four companies (Pfizer, Merck, Novo Nordisk, Crucell). The... »

Does biotech need pharma?

Does biotech need pharma?

  Biowebspin, July 30th, 2015 Does biotech need pharma? by Alison Taunton-Rigby, in Drug Discovery Today, 2001   See the article and check access: If you can't access this article, do not hesitate to contact us. »

Drug discovery in pharmaceutical industry: productivity challenges and trends

Drug discovery in pharmaceutical industry: productivity challenges and trends

  Biowebspin, July 30th, 2015 Drug discovery in pharmaceutical industry: productivity challenges and trends by Ish Khanna , in Drug Discovery Today, 2012 Low productivity, rising R&D costs, dissipating proprietary products and dwindling pipelines are driving the pharmaceutical industry to unprecedented challenges and scrutiny. In this article I reflect on the current status of the pharmaceutic... »

Grants4Targets – an innovative approach to translate ideas from basic research into novel drugs

Grants4Targets – an innovative approach to translate ideas from basic research into novel drugs

  Biowebspin, July 30th, 2015 Grants4Targets – an innovative approach to translate ideas from basic research into novel drugs by Monika Lessl, Stefanie Schoepe, Anette Sommer, Martin Schneider, Khusru Asadullah, in Drug Discovery Today, 2011 Collaborations between industry and academia are steadily gaining importance. To combine expertises Bayer Healthcare has set up a novel open innovation approa... »

Grants4Targets: an open innovation initiative to foster drug discovery collaborations

Grants4Targets: an open innovation initiative to foster drug discovery collaborations

  Biowebspin, July 30th, 2015 Grants4Targets: an open innovation initiative to foster drug discovery collaborations by Heidrun Dorsch, Alina Elisabeth Jurock, Stefanie Schoepe, Monika Lessl & Khusru Asadullah, in Nature Reviews Drug Discovery, 2015 Collaborations between academic institutions and the pharmaceutical industry are increasingly being pursued in the hope that these relationships co... »

Incorporating technical risk in compound real option models to value a pharmaceutical R&D licensing opportunity

Incorporating technical risk in compound real option models to value a pharmaceutical R&D licensing opportunity

  Biowebspin, July 30th, 2015 Incorporating technical risk in compound real option models to value a pharmaceutical R&D licensing opportunity by D. Cassimon, M. De Backer, P.J. Engelenc, M. Van Wouwee, V. Yordanov, in Research Policy, 2011 The valuation of multi-staged pharmaceutical R&D can be interpreted as a chain of real options. In valuing these compound option models, a crucial probl... »

Medicines discovery in the 21st century: the case for a stakeholder corporation

Medicines discovery in the 21st century: the case for a stakeholder corporation

  Biowebspin, July 30th, 2015 Medicines discovery in the 21st century: the case for a stakeholder corporation by J Dixon, P England, G Lawton, P Machin, A Palmer, in Drug Discovery Today, 2010 It is widely accepted that biopharmaceutical companies have, in recent times, failed to deliver large numbers of new medicines to patients and have simultaneously failed to deliver large financial returns to... »

Page 1 of 512345